Nuvectis reports 40% response rate for NXP200 in Phase 1b high-grade glioma study
NVCT•Nuvectis Pharma reported a 40% response rate for NXP200 in a Phase 1b study of high-grade glioma. The company said responses included complete responses, and no treatment-related adverse event led to discontinuation or death.
1. Phase 1b results
Nuvectis Pharma reported positive Phase 1b results for NXP200 in recurrent or progressive BRAF V600-mutated gliomas. Treatment produced durable responses, including complete responses, and some patients previously treated with BRAF inhibitors responded.
2. Safety profile
Nuvectis said NXP200 had a manageable safety profile. No treatment-related adverse event led to discontinuation or death.
